NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
07/01/2026
Back to search
Official data from USPTO
RETHYMIC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
07/01/2026
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
02/28/2019
Registration date
04/07/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/01/2026
Last transaction
07/01/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
OSAKA, JP
Examiner
AVENT, TEAGUE A
Current location
Historical data usage
Holders and representatives
Holders
SUMITOMO PHARMA CO., LTD.
SUMITOMO PHARMA SWITZERLAND GMBH
Enzyvant Therapeutics GmbH
Representatives
Jeffrey R. Cadwell Dorsey & Whitney LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use for the treatment of pediatric congenital athymia and thymus gland diseasesdisorders and conditionsimmune deficiency related thereto; pharmaceutical preparations for human usetissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseasesdisorders and conditionsimmune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of pediatric congenital athymia and thymus gland diseasesdisorders and conditionsimmune deficiency related thereto; biologic preparations for medical and therapeutic purposestissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseasesdisorders and conditionsimmune deficiency related thereto
Publications
History of USPTO decisions and trademark events.
25 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
07/01/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/29/2026
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/03/2026
E815
TEAS SECTION 8 & 15 RECEIVED
04/01/2026
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
03/18/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/07/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
04/07/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/21/2020
PUBO
PUBLISHED FOR OPPOSITION
01/21/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/01/2020
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
12/13/2019
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
12/06/2019
ALIE
ASSIGNED TO LIE
12/04/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/11/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/09/2019
DOCK
ASSIGNED TO EXAMINER
07/25/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/19/2019
GNRT
NON-FINAL ACTION E-MAILED
05/19/2019
CNRT
NON-FINAL ACTION WRITTEN
05/19/2019
DOCK
ASSIGNED TO EXAMINER
05/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/19/2019
NWAP
NEW APPLICATION ENTERED
03/04/2019
Continuous trademark protection
Get notified about every new filing that threatens RETHYMIC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.